These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23124750)

  • 1. The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae.
    Kwag HL; Kim HJ; Chang DY; Kim HJ
    J Microbiol; 2012 Oct; 50(5):813-20. PubMed ID: 23124750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.
    Wei M; Wang D; Li Z; Song S; Kong X; Mo X; Yang Y; He M; Li Z; Huang B; Lin Z; Pan H; Zheng Q; Yu H; Gu Y; Zhang J; Li S; Xia N
    Emerg Microbes Infect; 2018 Sep; 7(1):160. PubMed ID: 30254257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins.
    Bissett SL; Mattiuzzo G; Draper E; Godi A; Wilkinson DE; Minor P; Page M; Beddows S
    Vaccine; 2014 Nov; 32(48):6548-55. PubMed ID: 25203446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
    Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
    Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
    Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
    Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Codon optimization of the human papillomavirus type 58 L1 gene enhances the expression of soluble L1 protein in Saccharomyces cerevisiae.
    Kim HJ; Kwag HL; Kim HJ
    Biotechnol Lett; 2013 Mar; 35(3):413-21. PubMed ID: 23183918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
    Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
    J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
    Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
    Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
    Thönes N; Müller M
    Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity.
    Schädlich L; Senger T; Gerlach B; Mücke N; Klein C; Bravo IG; Müller M; Gissmann L
    J Virol; 2009 Aug; 83(15):7690-705. PubMed ID: 19457985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
    Kim SN; Jeong HS; Park SN; Kim HJ
    J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
    Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
    Front Immunol; 2020; 11():606569. PubMed ID: 33343580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
    Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
    J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralization of human papillomavirus by specific nanobodies against major capsid protein L1.
    Minaeian S; Rahbarizadeh F; Zarkesh-Esfahani SH; Ahmadvand D; Broom OJ
    J Microbiol Biotechnol; 2012 May; 22(5):721-8. PubMed ID: 22561868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimized yeast cell-free system: sufficient for translation of human papillomavirus 58 L1 mRNA and assembly of virus-like particles.
    Wang X; Liu J; Zheng Y; Li J; Wang H; Zhou Y; Qi M; Yu H; Tang W; Zhao WM
    J Biosci Bioeng; 2008 Jul; 106(1):8-15. PubMed ID: 18691524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.